In the present research, it was proposed to provide topical delivery of diclofenac sodium. Diclofenac sodium will be encapsulate in liposome and further loaded into a hydrogel and delivered through topical route. The lipid film hydration approach was used to create diclofenac sodium liposomes, which were then characterised by vesicle size, zeta potential, and entrapment effectiveness. The pH of the generated liposomal gels was within the permissible range of 7.0-7.2. The spreadability of the gels was assessed using slip and drag characteristics and was found to be between 10.45 and 12.32 gm.cm/sec. F1, F2, and F3 spreadabilities were determined to be 10.45±0.075,12.32±0.042 and 11.75±0.049 gm.cm/sec, respectively. The viscosities for F1, F2, and F3 were determined to be 1870±25 cps, 1895±33 cps, and 1875±21 cps, respectively. The percentage of cumulative medication (diclofenac sodium) released from F1, F2, and F3 liposomal gel formulations was 98.15%±17, 98.72%±2.4 and 96.27%±2.7 respectively.

Keywords: Liposomal hydrogel, Diclofenac sodium, Entrapment efficiency, Rheumatoid arthritis, Spreadability, Lipid film, Zeta potential.

[1] Ketabforoush, A.H., Aleahmad, M., Qorbani, M., Mehrpoor, G., Afrashteh, S., Mardi, S., & Dolatshahi, E. (2023). Bone mineral density status in patients with recent-onset rheumatoid arthritis. Journal of Diabetes & Metabolic Disorders, 22(1): 775–785. doi: https://doi.org/10.1007%2Fs40200-023-01200-w.

[2] Feldmann, M., & Maini, S.R. (2008). Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunological Reviews, 223(1): 7–19. 

[3] Finckh, A., Gilbert, B., Hodkinson, B., Bae, S.C., Thomas, R., Deane, K.D., Alpizar-Rodriguez, D., & Lauper, K. (2022). Global epidemiology of rheumatoid arthritis. Nature Reviews Rheumatology, 18(10): 591–602. doi: 10.1038/s41584-022-00827-y.

[4] Koushik, S., Joshi, N., Nagaraju, S., Mahmood, S., Mudeenahally, K., Padmavathy, R., Jegatheesan, S.K., Mullangi, R., & Rajagopal, S. (2017). PAD4: pathophysiology, current therapeutics and future perspective in rheumatoid arthritis. Expert Opinion on Therapeutic Targets, 21(4): 433–447. 

[5] Tayal, S., Tiwari, P., Sahu, V., & Sharma, S. (2023). Role of Liposome as Novel Carrier Molecule. International Journal of Pharma Professional's Research, 14(3): 141–150.

[6] Harris Jr, E.D. (1990). Rheumatoid arthritis: pathophysiology and implications for therapy. New England Journal of Medicine, 323(14): 996. doi:https://doi.org/10.1056/nejm199005033221805.

[7] Cooles, F.A., & Isaacs, J.D. (2011). Pathophysiology of rheumatoid arthritis. Current Opinion in Rheumatology, 23(3): 233–40. doi: 10.1097/BOR.0b013e32834518a3.

[8] Visser, H. (2005). Early diagnosis of rheumatoid arthritis. Best Practice & Research Clinical Rheumatology, 19(1): 55–72. doi: 10.1016/j.berh.2004.08.005.

[9] Aletaha, D., & Smolen, J.S. (2018). Diagnosis and management of rheumatoid arthritis: a review. Jama, 320(13): 1360–72. doi: 10.1001/jama.2018.13103.

[10] Kapoor, B., Singh, S.K., Gulati, M., Gupta, R., & Vaidya, Y. (2014). Application of liposomes in treatment of rheumatoid arthritis: quo vadis. The Scientific World Journal. 

[11] Richards, B.L., Richards, B.L., Whittle, S.L., vander Heijde, D.M., & Buchbinder, R. (2012). The efficacy and safety of antidepressants in inflammatory arthritis: a Cochrane systematic review. The Journal of Rheumatology Supplement, 90: 21–7. doi: 10.3899/jrheum.120338.

[12] Gaujoux-Viala, C., Smolen, J.S., Landewé, R., Dougados, M., Kvien, T.K., Mola, E.M., Scholte-Voshaar, M., van Riel, P., & Gossec, L. (2010). Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 69(6): 1004–9. doi: 10.1136/ard.2009. 127225.

[13] Whittle, S.L., Richards, B.L., & Buchbinder, R. (2013). Opioid analgesics for rheumatoid arthritis pain. Jama, 309(5): 485–6. doi: https://doi.org/10.1001/jama.2012.193412.

[14] Whittle, S.L., Richards, B.L., & Buchbinder, R. (2012). Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative. Rheumatology, 51(8): 1416–25. doi: 10.1093/rheumatology/kes032.

[15] Liacini, A., Sylvester, J., Li, W.Q., Huang, W., Dehnade, F., Ahmad, M., & Zafarullah, M. (2003). Induction of matrix metalloproteinase-13 gene expression by TNF-α is mediated by MAP kinases, AP-1, and NF-κB transcription factors in articular chondrocytes. Experimental Cell Research, 288(1): 208–17. doi: 10.1016/s0014- 4827(03)00180-0.

[16] Ichikawa, H., Takada, Y., Shishodia, S., Jayaprakasam, B., Nair, M.G., & Aggarwal, B.B. (2006). Withanolides potentiate apoptosis, inhibit invasion, and abolish osteoclastogenesis through suppression of nuclear factor-κB (NF-κB) activation and NF-κB–regulated gene expression. Molecular Cancer Therapeutics, 5(6): 1434–45. doi: 10.1158/1535-7163.MCT-06-0096.

[17] Combe, B., Landewe, R., Daien, C.I., Hua, C., Aletaha, D., Álvaro-Gracia, J.M., Bakkers, M., Brodin, N., Burmester, G.R., Codreanu, C., & Conway, R. (2017). 2016 update of the EULAR recommendations for the management of early arthritis. Annals of the Rheumatic Diseases, 76(6): 948–59. doi: 10.1136/annrheumdis-2016- 210602.

[18] Liu, D., Ahmet, A., Ward, L., Krishnamoorthy, P., Mandelcorn, E.D., Leigh, R., Brown, J.P., Cohen, A., & Kim, H. (2013). A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy, Asthma & Clinical Immunology, 9: 1–25. doi: 10.1186/1710-1492-9-30.

[19] Crofford, L.J. (2013). Use of NSAIDs in treating patients with arthritis. Arthritis Research & Therapy, 15(S3): S2. doi: https://doi.org/10.1186%2Far4174.

[20] Tayal, S., Tiwari, P., Sahu, V., & Sharma, S. (2023). Preparation and characterization of an antiviral gel. International Journal of Pharma Professional's Research, 14(4): 150–156.

[21] Leppert, W., Malec–Milewska, M., Zajaczkowska, R., & Wordliczek, J. (2018). Transdermal and topical drug administration in the treatment of pain. Molecules, 23(3): 681. doi: 10.3390/molecules23030681.

[22] Gulrez, S.K., Al-Assaf, S., & Phillips, G.O. (2011). Hydrogels: methods of preparation, characterisation and applications. Progress in molecular and environmental bioengineering-from analysis and modeling to technology applications, 117150. doi: 10.5772/24553.

[23] Thakur, S., Riyaz, B., Patil, A., Kaur, A., Kapoor, B., & Mishra, V. (2018). Novel drug delivery systems for NSAIDs in management of rheumatoid arthritis: An overview. Biomedicine & Pharmacotherapy, 106: 1011–1023. doi: https://doi.org/10.1016/j.biopha.2018.07.027.

[24] Shailesh, S., Neelam, S., Sandeep, K., & Gupta, G.D. (2009). Liposomes: a review. Journal of Pharmacy Research, 2(7): 1163–1167.

[25] Jithan, A.V., & Swathi, M. (2010). Development of topical diclofenac sodium liposomal gel for better antiinflammatory activity. International Journal of Pharmaceutical Sciences and Nanotechnology (IJPSN), 3(2): 986–93. doi: https://doi.org/10.37285/ijpsn.2010.3.2.12.

[26] Torchilin, V.P. (1985). Liposomes as targetable drug carriers. Critical Reviews in Therapeutic Drug Carrier Systems, 2(1): 65–115.

[27] Pham, D.T., Thao, N.T., Thuy, B.T., Tran, V.D., Nguyen, T.Q., & Nguyen, N.N. (2022). Silk fibroin hydrogel containing Sesbania sesban L. extract for rheumatoid arthritis treatment. Drug delivery, 29(1): 882–888. doi: https://doi.org/10.1080/10717544.2022.2050848.

Source of Funding:

This study has not received any funds from any organization.

Conflict of Interest:

The authors declare that they have no conflict of interest.

Consent for Publication:

The authors declare that they consented to the publication of this study.

Authors’ Contribution:

All the authors took part in data collection, literature review, analysis, and manuscript writing.